Only GnRH agonist with survival data to support its indication in breast cancer1‑4Explore efficacy data
Only ready-to-use biodegradable GnRH agonist implant1-5View administration guide
Only GnRH agonist with a suite of support services for patients with breast or prostate cancerGet savings and support details
A retrospective chart review found that switching luteinizing hormone-releasing hormone (LHRH) agonists may be an option for some patients with progressing prostate cancer6*
Testosterone remained at castration levels
69% of patients’ PSA decreased (n=27)
after 3 months on the second-line therapy6*
69.3% PSA decrease
at 3 months for patients who were switched from LUPRON DEPOT® to Zoladex6
- *The median change in PSA was -1.5 ng/mL (IQR -10.0, 0.8). p=0.01.
- The median duration of the effect was 5.2 months.
- ‡The median percent decrease in PSA for Zoladex to LUPRON DEPOT® was 6.4% (95% CI -81.5–26.2).
This retrospective chart review analyzed the effectiveness (as determined by PSA levels) of switching from LUPRON DEPOT® to Zoladex or vice versa in progressing, castration-resistant prostate cancer.6
- At least 3 months on initial LHRH
- Initiated dose of LUPRON DEPOT® 22.5 mg (3-month dose)
Initiated dose of Zoladex 10.8 mg (3-month dose)
To evaluate the PSA response and duration of the response.6
Key inclusion criteria:
At any point, men could undergo surgery or radiotherapy. However, only a single hormonal therapy (without an antiandrogen) was allowed after the third month in the study.6
- Men could have undergone any primary treatment (surgery or radiotherapy)
- Men must have only been treated with a single LHRH agonist alone (with up to 3 months of an initial antiandrogen)
- Men had to have CRPC (2 consecutive increasing PSA values)
- Castrate testosterone was at <40 ng/dL while on initial LHRH therapy and when initiating the next agonist
Considerations for changing therapies
- Published data are limited for switching stable prostate or breast cancer patients from LUPRON DEPOT® to Zoladex.
- There is no expert consensus on whether one agent is more effective than another.6-10
- There is no expert consensus on the potential benefits of initiating a second-line LHRH agonist treatment for prostate or breast cancer.6-10
- ZOLADEX® (goserelin acetate implant) 3.6 [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; 2020.
- LUPRON DEPOT® (leuprolide acetate for depot suspension) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2019.
- ELIGARD® (leuprolide acetate) [prescribing information]. Fort Collins, CO: Tolmar Pharmaceuticals Inc.; 2019.
- TRELSTAR® (triptorelin pamoate for injectable suspension) [prescribing information]. Irvine, CA: Allergan, Inc.; 2020.
- ZOLADEX® (goserelin acetate implant) 10.8 [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; 2020.
- Lawrentschuk N, Fernandes K, Bell D, et al. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J of Urol. 2011;185(3):848-854.
- Mottet N, Cornford P, van den Bergh RC, et al. Prostate Cancer. European Association of Urology website. 2001. Updated 2020. Accessed September 2, 2020. https://uroweb.org/guideline/prostate-cancer/?type=summary-of-changes.
- Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v69-v77.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2020. © National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed September 25, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.6.2020. © National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed September 25, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Important Safety Information about ZOLADEX
Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in patients with a known hypersensitivity to GnRH, GnRH agonist analogues, or any of the components in ZOLADEX
ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormonal changes that occur with ZOLADEX treatment. ZOLADEX should not be given to women with undiagnosed abnormal vaginal bleeding
Pregnancy must be excluded for use in benign gynecological conditions. Women should be advised against becoming pregnant while taking ZOLADEX. Effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy
Transient worsening of tumor symptoms, or the occurrence of additional signs and symptoms of breast cancer, may occasionally develop during the first few weeks of treatment. Some patients may experience a temporary increase in bone pain. Monitor patients at risk for complications of tumor flare
Hyperglycemia and an increased risk of developing diabetes or worsening of glycemic control in patients with diabetes have been reported in men receiving GnRH agonists like ZOLADEX. Monitor blood glucose levels and glycosylated hemoglobin (HbA1c) periodically and manage according to current clinical practice
Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists like ZOLADEX in men. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice
Hypercalcemia has been reported in some prostate and breast cancer patients with bone metastases after starting treatment with ZOLADEX. If hypercalcemia does occur, appropriate treatment measures should be initiated
Hypersensitivity, antibody formation and acute anaphylactic reactions have been reported with GnRH agonist analogues
ZOLADEX may cause an increase in cervical resistance. Therefore, caution is recommended when dilating the cervix for endometrial ablation
Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes
Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation
Treatment with ZOLADEX may be associated with a reduction in bone mineral density over the course of treatment. Data suggest a possibility of partial reversibility. In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients
In women the most frequently reported adverse reactions were related to hypoestrogenism. The adverse reaction profile was similar for women treated for breast cancer, dysfunctional uterine bleeding, and endometriosis
The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometriosis were: hot flashes (96%), vaginitis (75%), headache (75%), decreased libido (61%), emotional lability (60%), depression (54%), sweating (45%), acne (42%), breast atrophy (33%), seborrhea (26%), and peripheral edema (21%)
The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometrial thinning were: vasodilation/hot flashes (57%), headache (32%), sweating (16%), and abdominal pain (11%)
The most commonly reported adverse reactions with ZOLADEX in breast cancer clinical trials were hot flashes (70%), decreased libido (47.7%), tumor flare (23%), nausea (11%), edema (5%), and malaise/fatigue/lethargy (5%). Injection site reactions were reported in less than 1% of patients
The most commonly observed adverse reactions during ZOLADEX treatment for prostatic carcinoma were due to the expected physiological effects from decreased testosterone levels. The most common adverse reactions (incidence of >5% in prostate clinical trials) were:
For ZOLADEX 3.6-mg: Hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%)
For ZOLADEX 10.8-mg: Hot flashes (64%), pain (general) (14%), gynecomastia (8%), pelvic pain (6%), and bone pain (6%)
In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence >5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%). Treatment with ZOLADEX and flutamide did not add substantially to the toxicity of radiation treatment alone
Management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate in combination with flutamide. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy
Palliative treatment of advanced carcinoma of the prostate
Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months
Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding
Palliative treatment of advanced breast cancer in pre- and perimenopausal women
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088 or contact TerSera Therapeutics at 1-844-334-4035 or email@example.com.